American Pancreatic Association practice guidelines for chronic pancreatitis

Jump to navigation Jump to search

Chronic pancreatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic pancreatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Abdominal X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

American Pancreatic Association Practice Guidelines

APA Clinical Practice Guidelines for Chronic pancreatiits

American Pancreatic Association practice guidelines for chronic pancreatitis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of American Pancreatic Association practice guidelines for chronic pancreatitis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on American Pancreatic Association practice guidelines for chronic pancreatitis

CDC on American Pancreatic Association practice guidelines for chronic pancreatitis

American Pancreatic Association practice guidelines for chronic pancreatitis in the news

Blogs on American Pancreatic Association practice guidelines for chronic pancreatitis

Directions to Hospitals Treating Chronic pancreatitis

Risk calculators and risk factors for American Pancreatic Association practice guidelines for chronic pancreatitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]

American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: Evidence-Based Report on Diagnostic Guidelines[1]

Epidemiology and Risk Factors:

Recommendation Evidence Level Strength of Recommendation
Data on population-based estimates of CP are emerging. Low Conditional
A small fraction of patients progress from AP to CP. Moderate Conditional
Alcohol and smoking are independent risk factors for CP. Both are associated with disease progression, and their risks are likely multiplicative. High Strong
The spectrum of risk factors for CP has broadened. Low Conditional
Genetic discoveries are rapidly uncovering new susceptibility factors. Knowledge of gene and gene-environment interactions may translate into new diagnostic and treatment paradigms. Moderate Strong

Pathologic Definitions:

The usual level of evidence statements are generally not used in anatomic pathology.

Recommendation
Chronic pancreatitis is characterized by atrophy and fibrosis of the exocrine tissue with or without chronic inflammation.
Scarring of the parenchyma may be focal, patchy, or diffuse.
Progressive fibrosis and atrophy may lead to exocrine insufficiency (steatorrhea) followed by endocrine insufficiency (diabetes).
 Autoimmune pancreatitis can mimic pancreas carcinoma.

Ultrasound and Computed Tomography:

Recommendation Evidence Level Strength of Recommendation
Ultrasound and CT are best for the late findings of CP but are limited in the diagnosis of early or mild pancreatitis. Moderate Conditional
Intraductal pancreatic calcifications are the most specific and reliable sonographic and CT signs of CP. Moderate Strong
Computed tomography is helpful for the diagnosis of complications of CP. Moderate Strong
Computed tomography is helpful for diagnosis of other conditions that can mimic CP. Low Conditional

MRI Imaging

Recommendation Evidence Level Strength of Recommendation
Compared with ultrasound and CT, MRI is a more sensitive imaging tool for the diagnosis of CP. Moderate Conditional
Ductal abnormalities are very specific and reliable MRI signs of CP. Low Conditional
Signal intensity changes in the pancreas, seen on MRI, may precede ductal abnormalities and suggest early CP. Low Conditional
Stimulation of the pancreas using intravenous (IV) secretin may improve the diagnostic accuracy in the detection of ductal and parenchymal abnormalities seen in CP. Low Conditional

Endoscopic Ultrasound

Recommendation Evidence Level Strength of Recommendation
The ideal threshold number of EUS criteria necessary to diagnose CP has not been firmly established, but the presence of 5 or more and 2 or less strongly suggests or refutes the diagnosis of CP. Low Strong
The EUS features of CP are not necessarily pathologic and may occur as a normal aging, as a normal variant, or due to nonpathologic asymptomatic fibrosis in the absence of endocrine or exocrine dysfunction. Low Strong
The relatively poor interobserver agreement (IOA) for EUS CP features limits the diagnostic accuracy and overall utility of EUS for diagnosing CP. Moderate Strong

Endoscopic Retrograde Cholangiopancreatography

Recommendation Evidence Level Strength of Recommendation
Endoscopic retrograde pancreatogram (ERP) is rarely used for diagnostic purposes. Moderate Strong
The correlation between the Cambridge criteria and histology is highest in advanced CP. Moderate Strong
Multiple confounders limit the interpretation of ductal changes by Cambridge criteria. Low Strong

Indirect Pancreatic Function Testing

Recommendation Evidence Level Strength of Recommendation

Direct Pancreatic Function Tests

Recommendation Evidence Level Strength of Recommendation

Correlation of Imaging and Function With Histology

Recommendation Evidence Level Strength of Recommendation

References

  1. Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, Wu BU, Forsmark CE, Vege SS (2014). "American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines". Pancreas. 43 (8): 1143–62. doi:10.1097/MPA.0000000000000237. PMC 5434978. PMID 25333398.

Template:WSTemplate:WH